Back to Browse Journals » Vascular Health and Risk Management » Volume 6

Type 2 diabetes: postprandial hyperglycemia and increased cardiovascular risk

Authors Ajikumar V Aryangat, John E Gerich

Published 9 March 2010 Volume 2010:6 Pages 145—155

DOI http://dx.doi.org/10.2147/VHRM.S8216

Review by Single-blind

Peer reviewer comments 4

Ajikumar V Aryangat, John E Gerich
University of Rochester, Rochester, New York, USA
Abstract: Hyperglycemia is a major risk factor for both the microvascular and macrovascular complications in  patients with type 2 diabetes. This review summarizes the cardiovascular results of large outcomes trials in diabetes and presents new evidence on the role of hyperglycemia, with particular emphasis on postprandial hyperglycemia, in adverse cardiovascular outcomes in patients with type 2 diabetes. Treatment options, including the new dipeptidyl peptidase-4 inhibitors and glucagon-like peptide-1 mimetics that primarily target postprandial hyperglycemia, are also discussed. Hyperglycemia increases cardiovascular mortality, and reducing hyperglycemia lowers cardiovascular risk parameters. Control of both fasting and postprandial hyperglycemia is necessary to achieve optimal glycated hemoglobin control. Therefore, antihyperglycemic agents that preferentially target postprandial hyperglycemia, along with those that preferentially target fasting hyperglycemia, are strongly suggested to optimize individual diabetes treatment strategies and reduce complications.
Keywords: postprandial hyperglycemia, diabetes mellitus, drugs, cardiovascular risk

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF] 

 

Other article by this author:

Readers of this article also read:

Nanoformulated cell-penetrating survivin mutant and its dual actions

Sriramoju B, Kanwar RK, Kanwar JR

International Journal of Nanomedicine 2014, 9:3279-3298

Published Date: 10 July 2014

Effects on cardiovascular disease risk of a web-based health risk assessment with tailored health advice: a follow-up study

Ersen B Colkesen, Bart S Ferket, Jan GP Tijssen, et al

Vascular Health and Risk Management 2011, 7:67-74

Published Date: 9 February 2011

Optimal management of familial hypercholesterolemia: treatment and management strategies

Mohammad Hassan Nemati, Behrooz Astaneh

Vascular Health and Risk Management 2010, 6:1079-1088

Published Date: 3 December 2010

Argatroban in the management of heparin-induced thrombocytopenia

Luciano Babuin, Vittorio Pengo

Vascular Health and Risk Management 2010, 6:813-819

Published Date: 1 September 2010

Blocking the RAAS at different levels: an update on the use of the direct renin inhibitors alone and in combination

Francesca Cagnoni, Christian Achiri Ngu Njwe, Augusto Zaninelli, et al

Vascular Health and Risk Management 2010, 6:549-559

Published Date: 28 June 2010

Role of valsartan, amlodipine and hydrochlorothiazide fixed combination in blood pressure control: an update

Maurizio Destro, Francesca Cagnoni, Antonio D’Ospina, et al

Vascular Health and Risk Management 2010, 6:253-260

Published Date: 14 April 2010

Atorvastatin in stroke: a review of SPARCL and subgroup analysis

Branko N Huisa, Andrew B Stemer, Justin A Zivin

Vascular Health and Risk Management 2010, 6:229-236

Published Date: 30 March 2010

Prevalence and risk factors of microalbuminuria in Thai nondiabetic hypertensive patients

Pongsathorn Gojaseni, Angkana Phaopha, Worawon Chailimpamontree, et al

Vascular Health and Risk Management 2010, 6:157-165

Published Date: 11 March 2010

On the antiatherogenic effects of vitamin E: the search for the Holy Grail

Francesco Galli, Dimitrios Kirmizis, Dimitrios Chatzidimitriou

Vascular Health and Risk Management 2010, 6:69-71

Published Date: 16 February 2010

Coenzyme Q10 effects in neurodegenerative disease

Meredith Spindler, M Flint Beal, Claire Henchcliffe

Neuropsychiatric Disease and Treatment 2009, 5:597-610

Published Date: 9 November 2009